<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Evaluation of Triglyceride-Glucose (TyG) index in individuals living with HIV under antiretroviral therapy (ART)

dc.contributor.authorKaya, Bulent
dc.contributor.authorSahin, Suzan
dc.contributor.authorGencer, Serap
dc.date.accessioned2026-11-05T11:02:21Z
dc.date.issued2025
dc.description.abstractIntroduction Fasting triglyceride-glucose (TyG) index, which indirectly evaluates insulin resistance, is an important risk parameter in various diseases, especially cardiovascular diseases (CVD). There are very limited number of studies evaluating TyG index in individuals living with HIV, where the incidence of these diseases is increased. This study was conducted to determine the change in TyG index during the first year of antiretroviral therapy and the relationship between TyG index and CD4/CD8 ratio. Methods Data of patients living with HIV who were followed up between 2011 and 2024 were retrospectively analyzed. 343 ART-naive, non-diabetic patients who completed their first year of follow-up under ART were included in the study. TyG index was calculated according to the formula Ln [fasting triglyceride (mg/dL) x fasting glucose (mg/dL)/2]. Patients with TG values >150 mg/dl at the time of diagnosis constituted the hypertriglyceridemic (HTG) group, and patients with TG values <= 150 mg/dl at the time of diagnosis constituted the non-hypertriglyceridemic (NHTG) group. Results Hypertriglyceridemia was detected in 143 (42%) of our patients in the initial evaluation at the time of diagnosis. No correlation was found between TyG index and lymphocyte subgroups at the time of diagnosis (p > 0.05). However, a positive linear correlation was found between TyG index and CD4 + and CD8 + T cell counts (r = 0.073, p = 0.035; r = 0.181, p < 0.001, respectively) during the first year of ART. TyG index did not show any significant change in the months after starting ART in the NHTG group, while it decreased statistically significantly in the HTG group (p < 0.001). Conclusion The decrease in TyG index with control of immune activation under ART is promising as an important follow-up parameter. Therefore, data from new prospective studies are needed to analyze conditions such as CVD and metabolic syndrome that will occur in the longer term under ART.
dc.description.issue1
dc.description.pages1562
dc.description.volume25
dc.identifier.doi10.1186/s12879-025-12011-0
dc.identifier.issn1471-2334
dc.identifier.urihttps://doi.org/10.1186/s12879-025-12011-0
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/10901
dc.identifier.wosWOS:001615544300016
dc.language.isoen
dc.publisherBMC
dc.relation.hasversion10.1186/s12879-025-12011-0
dc.relation.ispartofBMC INFECTIOUS DISEASES
dc.subjectHIV
dc.subjectTriglyceride-Glucose index
dc.subjectTyG index
dc.subjectCD4/CD8 RATIO
dc.subjectDISEASES
dc.subjectADULTS
dc.subjectInfectious Diseases
dc.titleEvaluation of Triglyceride-Glucose (TyG) index in individuals living with HIV under antiretroviral therapy (ART)
dc.typeArticle
oaire.citation.editionScience Citation Index Expanded (SCI-EXPANDED)
oaire.citation.issue1
oaire.citation.volume25
person.identifier.orcid0000-0002-7124-3363
person.identifier.orcid0000-0002-3217-6305
person.identifier.orcid0000-0003-3027-5868
person.identifier.ridACM-6042-2022
person.identifier.ridE-3471-2015
person.identifier.ridKSM-8651-2024

Files

Collections